Table 3.
Univariate and multivariate analysis of EZH2 gain and clinicopathologic factors associated with overall survival in mucosal melanoma.
| Variable | OS | |||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | |||||
| HR | 95% CI | p Value | HR | 95% CI | p Value | |
| Age (>60 years/≤60 years) | 0.83 | 0.54–1.28 | 0.40 | |||
| Gender (female/male) | 0.75 | 0.50–1.14 | 0.179 | |||
| Primary site (Head and Neck/non-Head and Neck) | 1.49 | 0.83–2.70 | 0.18 | |||
| Ulceration (yes/no) | 1.21 | 0.74–1.99 | 0.442 | |||
| TNM stage (I + II/III + IV) | 1.39 | 0.90–2.14 | 0.136 | |||
| BRAF mutation (yes/no) | 0.93 | 0.45–1.92 | 0.84 | |||
| NRAS mutation (yes/no) | 1.17 | 0.48–2.89 | 0.729 | |||
| CKIT mutation (yes/no) | 0.92 | 0.34–2.52 | 0.875 | |||
| EZH2 gain (yes/no) | 1.65 | 1.10–2.48 | 0.017 | 1.61 | 1.02–2.56 | 0.041 |